{"nctId":"NCT02271230","briefTitle":"Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure","startDateStruct":{"date":"2014-08"},"conditions":["Heart Failure"],"count":25871,"armGroups":[{"label":"Vitamin D and fish oil","type":"EXPERIMENTAL","interventionNames":["Drug: Vitamin D and fish oil"]},{"label":"Vitamin D alone","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vitamin D alone"]},{"label":"Fish oil (EPA/DHA) alone","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Fish oil (EPA/DHA) alone"]},{"label":"Fish oil and vitamin D placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Vitamin D and fish oil","otherNames":[]},{"name":"Fish oil (EPA/DHA) alone","otherNames":[]},{"name":"Vitamin D alone","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men aged 50 or older or women aged 55 or older\n* Be consuming no more than 800 IU of vitamin D from all supplemental sources combined (individual vitamin D supplements, calcium+vitamin D supplements, medications with vitamin D \\[e.g., Fosamax Plus D\\], and multivitamins), or, if taking, willing to decrease or forego such use during the trial;\n* Be consuming no more than 1200 mg/d of calcium from all supplemental sources combined, or, if taking, willing to decrease or forego such use during the trial;\n* Not be taking fish oil supplements, or, if taking, willing to forego their use during the trial\n\nExclusion Criteria:\n\n* prevalent heart failure\n* History of cancer (except non-melanoma skin cancer), heart attack, stroke, transient ischemic attack, angina pectoris, CABG, or PCI\n* History of renal failure or dialysis, hypercalcemia, hypo- or hyperparathyroidism, severe liver disease (cirrhosis), or sarcoidosis or other granulomatous diseases such as active chronic tuberculosis or Wegener's granulomatosis;\n* Allergy to fish or soy","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With New Heart Failure Hospitalization","description":"We will consider any hospitalization for heart failure among participants enrolled in the parent VITAL trial for this ancillary study. Incident heart failure are initially captured through annual questionnaires with subsequent validation by a team of physicians with expertise in cardiovascular medicine and epidemiology. We excluded 36 participants with prevalent heart failure at the time of randomization for the primary analysis.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"240","spread":null},{"groupId":"OG001","value":"259","spread":null},{"groupId":"OG002","value":"244","spread":null},{"groupId":"OG003","value":"255","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Recurrent Heart Failure Hospitalization","description":"Recurrent heart failure hospitalizations ascertained either by review of medical records and/or use of CMS (Center for Medicare and Medicaid Services) data.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"341","spread":null},{"groupId":"OG001","value":"364","spread":null},{"groupId":"OG002","value":"326","spread":null},{"groupId":"OG003","value":"379","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1673,"n":12927},"commonTop":["Diarrhea","Constipation","Stomach upset or pain","Nausea","Easy bruising"]}}}